探花精选

Volker Lauschke

Volker Lauschke

Professor
E-postadress: volker.lauschke@ki.se
Telefon: +46852487711
Mobiltelefon: +46704926778
叠别蝉枚办蝉补诲谤别蝉蝉: Solnav盲gen 9, Biomedicum, 17165 Solna
Postadress: C3 Fysiologi och farmakologi, C3 FyFa Individanpassad medicin och l盲kemedelsutveckling, 171 77 Stockholm
Del av:

Artiklar

  • Article: JOURNAL OF CHEMICAL INFORMATION AND MODELING. 2025
    Tzoupis H; Papadourakis M; Papavasileiou KD; Burk O; Lauschke VM; Tsoumanis A; Melagraki G; Afantitis A
  • Article: PHARMACOLOGICAL RESEARCH. 2025;221:107998
    Klein K; Burk O; Tremmel R; Buettner FA; Kaestle L; Schroth W; Muerdter TE; Eccles D; Schmidt A-C; Nie脽 H; Zanger UM; Schwab M; Lauschke VM
  • Article: MOLECULAR AND CELLULAR BIOCHEMISTRY. 2025;480(10):5501-5519
    Codenotti S; Lauschke VM; Casella EV; Andersson DC; Fanzani A; Gastaldello S
  • Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2025;:110751
    Gr盲tz L; Turku A; Kozielewicz P; Bowin C-F; Scharf MM; Voss JH; Kinsolving J; Shekhani R; Oliva-Vilarnau N; Koolmeister T; K枚rber M; Lauschke VM; L枚ber S; Gmeiner P; Schulte G
  • Journal article: CELL. 2025;188(19):5429-5431
    Motso A; Pelcman B; Kalinovich A; Kahlous NA; Bokhari MH; Dehvari N; Halleskog C; Waara E; de Jong J; Cheesman E; Kallenberg C; Yakala GK; Murad P; Wetterdal E; Andersson P; van Beek S; Sandstr枚m A; Alleluia DN; Talamonti E; Youhanna S; Sabatier P; Koenig C; Willems S; Kemas AM; Hutchinson DS; Ham S; Gr盲tz L; Voss J; Marchan-Alvarez JG; Priede M; Jaunsleine K; Spura J; Kovada V; Supe L; Stoddart LA; Holliday ND; Newton PT; Pillon NJ; Schulte G; Summers RJ; Mutule I; Suna E; Olsen JV; Molenaar P; Carlsson J; Lauschke VM; Wright SC; Bengtsson T
  • Article: CELL. 2025;188(19):5142-5156.e23
    Motso A; Pelcman B; Kalinovich A; Kahlous NA; Bokhari MH; Dehvari N; Halleskog C; Waara E; de Jong J; Cheesman E; Kallenberg C; Yakala GK; Murad P; Wetterdal E; Andersson P; van Beek S; Sandstr枚m A; Alleluia DN; Talamonti E; Youhanna S; Sabatier P; Koenig C; Willems S; Kemas AM; Hutchinson DS; Ham S; Gr盲tz L; Voss J; Marchan-Alvarez JG; Priede M; Jaunsleine K; Spura J; Kovada V; Supe L; Stoddart LA; Holliday ND; Newton PT; Pillon NJ; Schulte G; Summers RJ; Mutule I; Suna E; Olsen JV; Molenaar P; Carlsson J; Lauschke VM; Wright SC; Bengtsson T
  • Article: BIOTECHNOLOGY AND BIOENGINEERING. 2025;122(9):2522-2534
    Kaellen A; Taebnia N; Widhe M; Lauschke VM; Hedhammar M
  • Article: MOLECULAR METABOLISM. 2025;99:102200
    Smith JAB; Gabriel BM; Brady AJ; Abdelmoez AM; Savikj M; Wright SC; Koutsilieri S; Barres R; Lauschke VM; Krook A; Zierath JR; Pillon NJ
  • Article: BRITISH JOURNAL OF PHARMACOLOGY. 2025;182(14):3353-3370
    Gasbjerg LS; Rasmussen RS; Dragan A; Lindquist P; Melchiorsen JU; Stepniewski TM; Schiellerup S; Tordrup EK; Gadgaard S; Kizilkaya HS; Willems S; Zhong Y; Wang Y; Wright SC; Lauschke VM; Hartmann B; Holst JJ; Selent J; Rosenkilde MM
  • Article: CHEMISTRY-A EUROPEAN JOURNAL. 2025;31(33):e202500382
    Kehler M; Zhou K; Kemas AM; del Prado A; Hutchinson ES; Nairn EH; Varga M; Plattner Y; Zhong Y; Purewal-Sidhu O; Haslam J; Wiita E; Gildie H; Singerova K; Szaruga Z; Almloef I; Hormann FM; Liu K-C; Wallner O; Ortis F; Homan EJ; Gileadi O; Rudd SG; Stenmark P; de Vega M; Helleday T; D'Arcy-Evans ND; Lauschke VM; Michel M
  • Article: CHEMBIOCHEM. 2025;26(11):e202500220
    Visnes T; Zhou K; Kemas AM; Campopiano D; Lauschke VM; Michel M
  • Article: IMETA. 2025;4(3):e70038
    Pan L; Tang B; Zhang X; Parini P; Tremmel R; Loscalzo J; Lauschke VM; Maron BA; Paci P; Ernberg I; Tan NS; Vegvari A; Liao Z; Rengarajan S; Zubarev R; Fan Y; Zheng X; Jian X; Sheng R; Wang Z; Li X
  • Journal article: ENDOCRINE ABSTRACTS. 2025
    Dekanski A; Li C; Schobloch L; Lindgren E; Wright S; Ferreira D; Lauschke V; Taebnia N; Stener-Victorin E
  • Article: JCI INSIGHT. 2025;10(8):e180943
    Haag M; Winter S; Kemas AM; Tevini J; Feldman A; Eder SK; Felder TK; Datz C; Paulweber B; Liebisch G; Burk O; Lauschke VM; Aigner E; Schwab M
  • Journal article: IMETA. 2025;4(3)
    Comprehensive analysis of multi鈥恛mics single鈥恈ell data using the single鈥恈ell analyst
    Pan L; Tang B; Zhang X; Parini P; Tremmel R; Loscalzo J; Lauschke VM; Maron BA; Paci P; Ernberg I; Tan NS; V茅gv谩ri 脕; Liao Z; Rengarajan S; Zubarev R; Fan Y; Zheng X; Jian X; Sheng R; Wang Z; Li X
  • Article: DRUG METABOLISM AND DISPOSITION. 2025;53(4):100062
    Bruecker L; Jacob D; Preiss LC; Zhong Y; Geist F; Hewitt P; Lauschke VM; Petersson C
  • Journal article: ENGINEERING. 2025
    Sheng H; Liang Y; Lauschke VM; Wang Y
  • Article: MICROORGANISMS. 2025;13(3):534
    Ova AO; Joffre E; Shafagh RZ; Assuncao MFG; Sidorov RY; Santos LMA; Lauschke VM; Romling U
  • Article: NUCLEIC ACIDS RESEARCH. 2025;53(D1):D1498-D1509
    Tremmel R; Zhou Y; Camara MD; Laarif S; Eliasson E; Lauschke VM
  • Article: METHODS IN MOLECULAR BIOLOGY. 2025;2924:205-215
    Keulen J; Kemas A; Youhanna S; Shafagh RZ; Lauschke VM
  • Visa fler

Alla 枚vriga publikationer

  • Review: BIOMATERIALS. 2025;327:123739
    Nasiri R; Madadelahi M; Nikmaneshi MR; Gokce B; Bijarchi MA; Shah S; Tirp谩kov谩 Z; Van Gastel D; Taebnia N; de Barros NR; Zhu Y; Morcimen ZG; Gulicli B; Habibey R; Sendemir A; Jain S; Enrico A; Lauschke VM; Dokmeci MR; Pratx G; Khademhosseini A; Herland A
  • Review: ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY. 2025
    Wright SC; Lindquist P; Rosenkilde MM; Lauschke VM
  • Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2025;26(18):8761
    Moghazy M; Papathanasiou M; Tzoupis H; Papavasileiou KD; Xing C; Lauschke VM; Afantitis A; Melagraki G
  • Review: ANNALS OF HUMAN GENETICS. 2025;89(5):384-397
    Zhou Y; Park Y; Camara MD; Lauschke VM
  • Preprint: ARXIV. 2025
    Honor脙漏 A; G脙隆lvez BR; Park Y; Zhou Y; Lauschke VM; Xiao M
  • Review: EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY. 2025;21(5):563-577
    Zhou Y; Zhong Y; Lauschke VM
  • Review: PHARMACOGENOMICS. 2025;26(5-6):171-182
    Tremmel R; Honore A; Park Y; Zhou Y; Xiao M; Lauschke VM
  • Preprint: CHEMRXIV. 2025
    Kehler M; Zhou K; Kemas A; del Prado A; Scaletti Hutchinson E; Hesslefors Nairn E; Varga M; Plattner Y; Zong Y; Purewal-Sidhu O; Haslam J; Wiita E; Gildie H; Singerova K; Szaruga Z; Alml枚f I; Hormann F; Liu K-C; Wallner O; Ortis F; Homan E; Gileadi O; Rudd S; Stenmark P; de Vega M; Helleday T; D'Arcy-Evans N; Lauschke V; Michel M
  • Preprint: BIORXIV. 2025
    Romero AL; Preka E; Pizzirusso G; Arroyo-Garc铆a LE; Zisiadis GA; Oliva-Vilarnau N; Ruchiy Y; Seitz T; Zhou K; Isla A; Friess L; Sun Y; Canut MQ; Shamikh A; Xu Y; Zhu C; Rodrigues C; Fisahn A; Joseph B; Carlson L-M; Fragkopoulou A; Lauschke V; Betsholtz C; Osman A; Blomgren K
  • Review: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2025;91(2):252-263
    Tremmel R; Pirmann S; Zhou Y; Lauschke VM
  • Preprint: BIORXIV. 2025
    Jiang H; Derisoud E; Parreira D; Taebnia N; Jannig P; Shafagh RZ; Zhao A; Li C; Ortiz M; Maliqueo MA; Stener-Victorin E; Lauschke V; Deng Q
  • Preprint: BIORXIV. 2025
    Codenotti S; Lauschke V; Casella E; Andersson D; Fanzani A; Gastaldello S
  • Preprint: BIORXIV. 2025
    Zhao Q; De Nardo W; Wang R; Zhong Y; Keles U; Sakalauskaite G; Zhao LN; Tay H; Youhanna S; Yan M; Xie Y; Kim Y; Lee S; Lim RL; Teo G; Narayanaswamy P; Burton P; Lauschke V; Choi H; Watt M; Kaldis P
  • Review: DRUG METABOLISM REVIEWS. 2025;57(1):67-90
    Li K; Lauschke VM; Zhou Y
  • Conference publication: PHARMACOGENETICS AND GENOMICS. 2025;35(1):27-28
    Gonzalez-Padilla D; Zhou Y; Lauschke V
  • Review: PHARMACOLOGICAL REVIEWS. 2024;76(6):1089-1101
    Weitzberg E; Ingelman-Sundberg M; Lundberg JO; Engberg G; Schulte G; Lauschke VM
  • Editorial comment: SIGNAL TRANSDUCTION AND TARGETED THERAPY. 2024;9(1):269
    Zhong Y; Lauschke VM
  • Review: DRUG METABOLISM AND DISPOSITION. 2024;52(6):467-475
    Ingelman-Sundberg M; Lauschke VM
  • Editorial comment: ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY. 2024;44(5):1098-1100
    Taebnia N; Lauschke VM
  • Preprint: BIORXIV. 2024
    Smith JAB; Gabriel B; Abdelmoez A; Savikj M; Wright S; Koutsilieri S; Barr猫s R; Lauschke V; Krook A; Zierath J; Pillon N
  • Visa fler

Forskningsbidrag

  • Swedish Research Council
    1 December 2024 - 30 November 2027
    Primary human hepatocytes rapidly lose their functionality in conventional 2D cultures, which significantly limits their usefulness as an in vitro model to study hepatotoxicity, particularly of biological and nanoparticle therapeutics, which commonly accumulate and exert their effects over prolonged periods of time. Thus, in the absence of relevant in vitro systems, animal models constitute a cornerstone to predict the toxicity of newly developed biologics. The liver is however an organ with pronounced species differences with regards to expression and catalytic activities of factors involved in drug absorption, distribution, metabolism and excretion. This is further amplified for nucleotide- and antibody-based therapeutics where sequence and epitope differences between species are common problems during preclinical development.We have previously developed a 3D human liver model that accurately predicts the hepatotoxicity of small molecules, which is by now widely used in industry. Here, we aim to extend this work and develop and benchmark a platform that can predict hepatotoxicity and liver biodistribution of biologics (antisense oligonucleotides, siRNAs, therapeutic antibodies) and different nanoparticles (lipid-based, polymeric and inorganic). This system aspires to improve the predictability and translatability of findings as well as to mitigate the need for animal models, thus reducing the number of animals needed in pre-clinical discovery and development.
  • Swedish Research Council
    1 January 2024 - 31 December 2028
    Non-alcoholic steatohepatitis (NASH) is a prevalent liver disease that affects up to 2-6% of the general population and 15-40% of obese persons. NASH is characterized by steatosis, chronic inflammation and hepatocyte injury and is prone to progress into liver cirrhosis and liver cancer. However, despite tremendous efforts, there are currently no approved treatments for NASH. NASH is closely linked to obesity, sarcopenia, dyslipidemia and insulin resistance and it has become clear that multiple extrahepatic tissues, including pancreas, skeletal muscle and adipose tissue produce signals that orchestrate hepatic metabolism, inflammation and fibrosis. However, the underlying mechanisms in humans remain poorly understood.Here, we will integrate patient-derived ex vivo tissue models of liver, pancreas, skeletal muscle and fat to comprehensively map human metabolic crosstalk. By analyzing the secretome from healthy and diseased individuals, we will identify novel endocrine signals that contribute to NASH etiology and progression. Moreover, we will use the established platform to screen chemogenomic libraries to identify compounds that activate 鈥渉ealthy鈥 signals or inhibit 鈥渄isease鈥 cues. This project thus provides a conceptually novel perspective that considers NASH as a complex pathology caused by dysregulated tissue interactions and targets these disease mechanisms, which are neglected by current drug development programs, to finally develop effective treatments.
  • Chemogenomic profiling of nuclear hormone receptors as targets for NASH
    Novo Nordisk Foundation
    1 November 2023 - 31 October 2025
  • Swedish Research Council
    1 January 2023 - 31 December 2026
    The availability of relevant in vitro models of tissue units would be highly valuable for our struggles to understand human biology and physiology to obtain better health solutions. In the native tissue, cells are organized by a supporting extracellular matrix (ECM) in various types of microenvironments. ECM proteins build up the frameworks of these different environments, e.g. interstitial fiber networks in connective tissue and basement membranes in biological barriers. It has lately become clear that cells in culture are largely affected by their microenvironment, and especially mechanotransduction and the availability of cell-cell and cell-matrix connections. We will herein use a functionalised recombinant spider silk protein to construct relevant ECM-mimics, both networks for parenchymal and support cells in tissue compartments, and membranes for their biological barriers. These we will use to survey the effect of different parameters of the environment for cells in culture. For investigations of biological processes, it is essential to include a combination of cellular compartments and biological barriers. We will use our obtained knowledge to construct physiologically relevant tissue units of 1) tumours in stroma with blood vessels, for investigations of the interplay between cancer cells and vasculature, as well as 2) tumours behind blood brain barrier (BBB), for investigation of treatment strategies of brain tumours.
  • Deutsche Forschungsgemeinschaft
    1 January 2023
    Non-alcoholic steatohepatitis (NASH) is a serious liver disease characterized by fat accumulation, inflammation, and fibrosis. It affects ~6% of the global population but lacks effective treatment options and is thus a severe 探花精选 and healthcare challenge. Pharmacological treatment options are urgently needed to address this unmet 探花精选 need. Therapeutic modulation of nuclear receptors (NRs), many of which crucially regulate hepatic metabolism and inflammation, is increasingly recognized as potential avenue to hepatoprotective NASH treatment. However, only a minor fraction of the 48 human NRs has been evaluated in this context and comprehensive understanding of the entire NR family鈥檚 involvement in NASH pathology is lacking. Growing evidence supports remarkable potential of many (orphan) NRs to mediate beneficial therapeutic effects in NASH. For example, relevant sex-specific differences in NASH incidence point to an involvement of steroid hormones which act via NR activation. The role of hormone sensing and other NRs in the disease complex urgently requires systematic and comprehensive evaluation for therapeutic potential. This project aims to close this gap by systematically probing NR modulation for therapeutic effects in a primary patient-derived tissue model following a chemogenomics (CG) strategy. To meet its main objective of achieving comprehensive understanding of the pharmacological role of NRs in NASH, the project will assemble a custom CG compound set to cover 鈮40 of the 48 human NRs and systematically assess the phenotypic outcomes of NR modulation in liver spheroids generated from primary human hepatocytes and non-parenchymal liver cells. Using such sophisticated in vitro model to mimic relevant disease characteristics aims to overcome incomplete translation from rodent model to patient in NASH and to capture individual and sex-specific differences. Primary evaluation will focus on anti-steatotic, anti-inflammatory, anti-fibrotic, and anti-oxidative effects in a global, sex-specific, and genotype-dependent manner. Subsequently, beneficial effects resulting from NR modulation will be orthogonally validated and analyzed in-depth for sex- and patient-specific roles, dependence on metabolic parameters, potential synergies of dual modulation, and signaling networks. This unprecedented systematic and comprehensive approach to explore NRs as therapeutic targets for NASH treatment will reveal uncharted potential of this protein family and address an urgent unmet 探花精选 need. Additionally, new insights into the roles of steroid hormones as well as sex- and patient-specific differences in NASH will offer significant biological advance and may suggest personalized treatment strategies.
  • Swedish Research Council
    1 January 2022 - 31 December 2025
    Non-alcoholic steatohepatitis (NASH) is a prevalent liver disease that affects up to 2-6% of the general population and 15-40% of obese persons. NASH is characterized by steatosis, chronic inflammation and hepatocyte injury and is prone to progress into liver cirrhosis and liver cancer. However, despite tremendous efforts, there are currently no approved treatments for NASH. NASH is closely linked to obesity, dyslipidemia and insulin resistance and it has become clear that that the adipose tissue produces many signals that control hepatic metabolism, inflammation and fibrosis. However, the underlying mechanisms in humans are poorly understood.Here, we will integrate patient-derived ex vivo tissue models of liver and fat to comprehensively map human fat-liver metabolic crosstalk. By analyzing the secretome of adipose tissue from lean insulin-sensitive and obese insulin-resistant individuals, we will identify novel endocrine signals of human fat that promote or prevent NASH. Moreover, we will use the established platform to screen libraries of lead-like molecules to identify compounds that activate 鈥渉ealthy鈥 signals or inhibit 鈥渄isease鈥 cues. This project thus provides a conceptually novel perspective that considers NASH as a complex pathology caused by dysregulated tissue interactions and targets these disease mechanisms, which are neglected by current drug development programs, to finally develop effective treatments.
  • Swedish Research Council
    1 December 2019 - 31 December 2022
  • Swedish Research Council
    1 January 2017 - 31 December 2020
  • Swedish Research Council
    1 January 2017 - 31 December 2019
  • Swedish Research Council
    1 January 2016 - 31 December 2016

础苍蝉迟盲濒濒苍颈苍驳补谤

  • Professor, Fysiologi och farmakologi, 探花精选, 2023-

Examina och utbildning

  • Docent, Farmakologi, 探花精选, 2018

Handledning

  • Handledning till doktorsexamen

    • Jibbe Keulen
    • Chen Xing

Nyheter fr氓n KI

Kalenderh盲ndelser fr氓n KI